Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Working Capital Changes: 2014-2025

Historic Other Working Capital Changes for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $35,000.

  • ImmunityBio's Other Working Capital Changes fell 5.41% to $35,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 136.76%. This contributed to the annual value of -$5.5 million for FY2024, which is 8.14% up from last year.
  • Per ImmunityBio's latest filing, its Other Working Capital Changes stood at $35,000 for Q3 2025, which was down 99.12% from $4.0 million recorded in Q2 2025.
  • ImmunityBio's 5-year Other Working Capital Changes high stood at $13.4 million for Q2 2022, and its period low was -$9.7 million during Q1 2023.
  • For the 3-year period, ImmunityBio's Other Working Capital Changes averaged around -$650,364, with its median value being $37,000 (2024).
  • As far as peak fluctuations go, ImmunityBio's Other Working Capital Changes slumped by 1,027.18% in 2023, and later skyrocketed by 11,328.57% in 2025.
  • Quarterly analysis of 5 years shows ImmunityBio's Other Working Capital Changes stood at -$517,000 in 2021, then surged by 513.35% to $2.1 million in 2022, then skyrocketed by 64.01% to $3.5 million in 2023, then slumped by 260.31% to -$5.6 million in 2024, then fell by 5.41% to $35,000 in 2025.
  • Its last three reported values are $35,000 in Q3 2025, $4.0 million for Q2 2025, and $242,000 during Q1 2025.